======= TRIP13 =======
== Gene Information ==
* **Official Symbol**: TRIP13
* **Official Name**: thyroid hormone receptor interactor 13
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=9319|9319]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q15645|Q15645]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=TRIP13&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20TRIP13|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/604507|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Plays a key role in chromosome recombination and chromosome structure development during meiosis. Required at early steps in meiotic recombination that leads to non-crossovers pathways. Also needed for efficient completion of homologous synapsis by influencing crossover distribution along the chromosomes affecting both crossovers and non-crossovers pathways. Also required for development of higher-order chromosome structures and is needed for synaptonemal-complex formation. In males, required for efficient synapsis of the sex chromosomes and for sex body formation. Promotes early steps of the DNA double- strand breaks (DSBs) repair process upstream of the assembly of RAD51 complexes. Required for depletion of HORMAD1 and HORMAD2 from synapsed chromosomes (By similarity). Plays a role in mitotic spindle assembly checkpoint (SAC) activation (PubMed:28553959). {ECO:0000250|UniProtKB:Q3UA06, ECO:0000269|PubMed:28553959}.
|AAA|
|meiotic recombination checkpoint|
|meiotic cell cycle checkpoint|
|female meiosis I|
|negative regulation of meiotic nuclear division|
|male germ cell nucleus|
|negative regulation of meiotic cell cycle|
|oocyte maturation|
|synaptonemal complex assembly|
|spindle checkpoint|
|mitotic spindle assembly checkpoint|
|spindle assembly checkpoint|
|mitotic spindle checkpoint|
|synaptonemal complex organization|
|negative regulation of mitotic metaphase/anaphase transition|
|male meiosis I|
|negative regulation of metaphase/anaphase transition of cell cycle|
|negative regulation of mitotic sister chromatid separation|
|negative regulation of chromosome separation|
|negative regulation of mitotic sister chromatid segregation|
|regulation of meiotic nuclear division|
|female meiotic nuclear division|
|negative regulation of sister chromatid segregation|
|negative regulation of chromosome segregation|
|oocyte development|
|negative regulation of mitotic nuclear division|
|oocyte differentiation|
|synapsis|
|male meiotic nuclear division|
|negative regulation of nuclear division|
|regulation of meiotic cell cycle|
|reciprocal meiotic recombination|
|regulation of mitotic metaphase/anaphase transition|
|homologous recombination|
|regulation of metaphase/anaphase transition of cell cycle|
|negative regulation of reproductive process|
|regulation of mitotic sister chromatid separation|
|homologous chromosome segregation|
|regulation of chromosome separation|
|chromosome organization involved in meiotic cell cycle|
|regulation of mitotic sister chromatid segregation|
|oogenesis|
|regulation of sister chromatid segregation|
|transcription coregulator activity|
|meiotic chromosome segregation|
|regulation of chromosome segregation|
|meiosis I|
|meiosis I cell cycle process|
|chromosome|
|female gamete generation|
|negative regulation of chromosome organization|
|anatomical structure maturation|
|spermatid development|
|meiotic nuclear division|
|mitotic cell cycle checkpoint|
|spermatid differentiation|
|cell maturation|
|regulation of reproductive process|
|meiotic cell cycle process|
|regulation of mitotic nuclear division|
|double-strand break repair|
|regulation of nuclear division|
|cell cycle checkpoint|
|negative regulation of mitotic cell cycle phase transition|
|nuclear chromosome segregation|
|DNA recombination|
|meiotic cell cycle|
|negative regulation of cell cycle phase transition|
|developmental maturation|
|germ cell development|
|chromosome segregation|
|nuclear division|
|negative regulation of mitotic cell cycle|
|organelle fission|
|negative regulation of cell cycle process|
|regulation of chromosome organization|
|cellular process involved in reproduction in multicellular organism|
|negative regulation of organelle organization|
|regulation of mitotic cell cycle phase transition|
|regulation of cell cycle phase transition|
|transcription by RNA polymerase II|
|DNA repair|
|spermatogenesis|
|male gamete generation|
|negative regulation of cell cycle|
|mitotic cell cycle process|
|regulation of mitotic cell cycle|
|transcription, DNA-templated|
|nucleic acid-templated transcription|
|RNA biosynthetic process|
|developmental process involved in reproduction|
|mitotic cell cycle|
|gamete generation|
|negative regulation of cellular component organization|
|DNA metabolic process|
|regulation of cell cycle process|
|cellular response to DNA damage stimulus|
|multicellular organismal reproductive process|
|sexual reproduction|
|multicellular organism reproduction|
|multi-organism reproductive process|
|cell cycle process|
|chromosome organization|
|identical protein binding|
|nucleobase-containing compound biosynthetic process|
|heterocycle biosynthetic process|
|aromatic compound biosynthetic process|
|regulation of cell cycle|
|regulation of organelle organization|
|organic cyclic compound biosynthetic process|
|cell cycle|
|reproductive process|
|reproduction|
|ATP binding|
|cellular nitrogen compound biosynthetic process|
|cell development|
|RNA metabolic process|
|cellular response to stress|
|cellular macromolecule biosynthetic process|
|macromolecule biosynthetic process|
|gene expression|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp187|proTAME 5μM R04 exp187]]|-4.23|
|[[:results:exp217|Mdivi-1 15μM R05 exp217]]|-3.84|
|[[:results:exp177|Apcin 25μM plus proTAME 2μM R04 exp177]]|-3.74|
|[[:results:exp46|HMS-I1 1μM R01 exp46]]|-3.45|
|[[:results:exp60|Vinblastine 0.002μM R01 exp60]]|-3.34|
|[[:results:exp460|BML-284 0.09μM R08 exp460]]|-3.27|
|[[:results:exp45|Docetaxel 0.002μM R01 exp45]]|-3.24|
|[[:results:exp59|UMK57 1μM R01 exp59]]|-3.09|
|[[:results:exp184|Ixabepilone 0.004 to 0.005μM on day4 R04 exp184]]|-2.77|
|[[:results:exp103|Taxol 0.004μM R03 exp103]]|-2.63|
|[[:results:exp190|Vincristine 0.0005μM R04 exp190]]|-2.34|
|[[:results:exp310|2-Methoxyestradiol 0.55μM R07 exp310]]|-2.08|
|[[:results:exp294|Nutlin-3A 1.6μM R06 exp294]]|-1.99|
|[[:results:exp6|Bortezomib 0.005μM R00 exp6]]|-1.93|
|[[:results:exp36|TRAIL 50ng/ml R00 exp36]]|-1.9|
|[[:results:exp231|Epothilone-B 0.0015μM R05 exp231]]|-1.88|
|[[:results:exp412|THZ531 0.11 to 0.125 to 0.35μM on day4 then day6 R07 exp412]]|-1.81|
|[[:results:exp242|Radicicol 0.16μM R05 exp242]]|-1.8|
|[[:results:exp27|Pimelic-diphenylamide-106 0.5μM R00 exp27]]|-1.73|
|[[:results:exp66|BI-D1870 3.15μM R02 exp66]]|1.73|
|[[:results:exp272|CHIR-124 0.04μM R06 exp272]]|1.89|
|[[:results:exp97|BI-6727 0.0125μM R03 exp97]]|2.17|
|[[:results:exp343|Centrinone 0.5μM R07 exp343]]|3.49|
|[[:results:exp95|BI-2536 0.0042μM R03 exp95]]|3.65|
|[[:results:exp17|DABN 20μM R00 exp17]]|5.07|
|[[:results:exp256|HMS-I1 10μM R06 exp256]]|6.17|
|[[:results:exp64|Nocodazole 0.2μM R02 exp64]]|6.63|
|[[:results:exp93|DABN racemic mixture R03 exp93]]|7.09|
|[[:results:exp244|SB743921 0.001μM R05 exp244]]|7.14|
|[[:results:exp33|Rotenone 2μM R00 exp33]]|7.3|
|[[:results:exp208|Vinblastine 0.015μM R05 exp208]]|7.56|
|[[:results:exp24|Nocodazole 0.2μM R00 exp24]]|7.81|
|[[:results:exp108|Vinblastine 0.2μM R03 exp108]]|7.82|
|[[:results:exp94|Nocodazole 0.1μM R03 exp94]]|8.13|
|[[:results:exp111|R-DABN 8μM R03 exp111]]|8.19|
^Gene^Correlation^
|[[:human genes:m:mad2l1bp|MAD2L1BP]]|0.858|
|[[:human genes:k:kntc1|KNTC1]]|0.828|
|[[:human genes:z:zw10|ZW10]]|0.789|
|[[:human genes:z:zwilch|ZWILCH]]|0.762|
|[[:human genes:m:mad1l1|MAD1L1]]|0.761|
|[[:human genes:b:bub1b|BUB1B]]|0.752|
|[[:human genes:m:mad2l1|MAD2L1]]|0.728|
|[[:human genes:r:rbm14|RBM14]]|0.684|
|[[:human genes:b:bub3|BUB3]]|0.678|
|[[:human genes:c:cdc20|CDC20]]|0.573|
|[[:human genes:f:fntb|FNTB]]|0.496|
|[[:human genes:f:fnta|FNTA]]|0.494|
|[[:human genes:c:cenpe|CENPE]]|0.437|
|[[:human genes:c:ccnb1|CCNB1]]|0.432|
Global Fraction of Cell Lines Where Essential: 16/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|1/28|
|bone|0/26|
|breast|0/33|
|central nervous system|1/56|
|cervix|1/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/16|
|kidney|0/21|
|liver|2/20|
|lung|3/75|
|lymphocyte|0/16|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/9|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|3/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 3692
* **Expression level (log2 read counts)**: 5.24
{{:chemogenomics:nalm6 dist.png?nolink |}}